🇺🇸 FDA
Pipeline program

Selinexor

20-2202.cc

Phase 2 small_molecule active

Quick answer

Selinexor for Multiple Myeloma in Relapse is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Multiple Myeloma in Relapse
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials